What does semaglutide packaging actually contain?

What physical components come in a Wegovy box?

A standard Wegovy pack contains one pre-filled injection pen alongside a patient information leaflet. The pen itself is an auto-injector: the needle is pre-attached and concealed behind a needle cap, the dose is factory-set, and the device locks permanently after the final injection. You will not find separate vials, syringes or loose needles in the box, the system is entirely self-contained by design.

The outer carton carries the full product name (semaglutide and the Wegovy brand), the exact dose strength in milligrams, the batch number, expiry date, MHRA licence information and storage conditions. The package insert repeats all of this and adds the full prescribing summary in patient-friendly language. If any of these elements are missing, misspelled or look different from a previous genuine pack, treat it seriously, counterfeit pens have been seized by the MHRA, some containing dangerous substitutes rather than semaglutide.

Novo Nordisk produces six distinct Wegovy carton variants for the UK, one per dose step from the 0.25 mg starter through to the 2.4 mg maintenance dose, plus the newer 7.2 mg presentation. Each uses colour-coding to reduce the risk of accidentally using the wrong strength during titration.

How does the Wegovy pen work, and why does the packaging reflect that?

The pen is designed around once-weekly subcutaneous injection into the abdomen, thigh or upper arm. Because semaglutide is administered at very low volumes (a fraction of a millilitre per dose) the pen is compact and the mechanism is straightforward: remove the cap, apply the pen to cleaned skin, press the button and hold until the injection is complete and the window confirms it.

The four-dose design matters to the packaging because each pen is a four-week supply at that strength. This is why a prescription written for one month of Wegovy typically corresponds to a single box. For context on how Wegovy comes packaged across different dose stages, the structure is consistent (one pen, four doses, one box) at every strength in the titration schedule.

The semaglutide medicine overview covers the pharmacology in more detail, but in packaging terms the relevant point is that semaglutide is a GLP-1 receptor agonist administered at weekly intervals, which is why the four-dose pen fits neatly into a monthly supply cadence. The NHS patient information for tirzepatide and semaglutide both follow the same principle of one pen equalling one pack, you can read the NHS guidance on semaglutide at nhs.uk/medicines/semaglutide.

What should you check when your Wegovy packaging arrives?

This is something our prescribers raise with patients more than you might expect, and if you've had a moment of doubt looking at a new box, you're not alone. Counterfeit GLP-1 medicines have appeared in the UK supply chain, predominantly sold through social media and unregistered online sellers. The MHRA has warned explicitly about fake weight-loss pens that have reached patients, some containing insulin rather than the labelled medicine.

When a box arrives from a legitimate UK pharmacy source, check the following: the outer carton has no smudged print, misaligned text or unusual fonts; the batch number and expiry date are clearly printed and legible; the pen inside matches the strength on the box; the patient information leaflet is present and printed in English. If any element looks wrong, do not use the pen, contact the pharmacy and report the product via the MHRA's Yellow Card scheme, which accepts reports of both suspected side effects and suspect products.

You can verify any online pharmacy dispensing Wegovy by checking the GPhC register at pharmacyregulation.org/registers. A pharmacy without a valid GPhC listing should not be supplying prescription medicines to UK patients. For more background on the Wegovy treatment itself, including its licensed indications and eligibility criteria, that overview page is a useful starting point.

Does the packaging change with the newer 7.2 mg Wegovy pen?

Yes, the 7.2 mg format is meaningfully different from the lower-dose pens. On 14 April 2026 the MHRA approved a dedicated single-dose 7.2 mg pen: one pre-set injection per week, an auto-dosing mechanism, a built-in covered needle and a device that locks after use. It is a single-dose pen rather than the four-dose design used at lower strengths, which means the box contents and format differ from earlier Wegovy packaging.

Clinically, 7.2 mg is approved only for adults with a BMI of 30 or above, it is not licensed for the lower BMI threshold that applies to some other Wegovy strengths. The starting dose for anyone new to Wegovy remains 0.25 mg, titrated upward by the prescriber; 7.2 mg is the maximum maintenance dose. The Wegovy pack formats page goes into further detail on how the different box types relate to the titration schedule.

Questions about cost, treatment options or whether Wegovy might be appropriate for you are best answered through a clinical assessment. You can check your eligibility through a free consultation with our prescribers, one of the team will review your details the same day.